Abstract
Background
Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients.
Methods
Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy.
Results
Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.
Similar content being viewed by others
Neoadjuvant trials of radiation prior to surgery offer the unique opportunity to study irradiated tissues in situ. We previously reported a Phase 1 trial of stereotactic body radiation therapy (SBRT), three fractions of 8 Gy delivered over 1 week, 2 weeks prior to radical prostatectomy (RP) for high-risk prostate cancer [1]. Pretreatment biopsies and surgical specimens from this trial were used to determine radiation-induced changes in T cell and macrophage subsets by multiplex immune-fluorescence (mIF).
The 6 out of 11 cases were chosen due to their availability of biopsy and RP cores for use. Biopsy cores were selected for analysis based on tumor content greater than 70%. For each case, the tissue block with the dominant tumor nodule in the radical prostatectomy was identified by hematoxylin and eosin staining prior to mIF. Parallel slides were stained with antibodies against T cells [CD3 (clone 2Gv6 rabbit mAb, Ventana cat. 790-4341), CD4 (clone SP35 rabbit mAb, Ventana cat 790-4423), CD8 (clone SP57 rabbit mAb, Ventana cat. 790-4460), FoxP3 (clone SP97 rabbit mAb, Spring Bioscience cat. M3970)] or macrophages [CD68 (clone KP-1 mouse mAb, Ventana cat. 790-2931), CD163 (clone MRQ26 mouse mAb, Ventana cat. 760-4437), CD11b (clone EPR1344 rabbit mAb, Abcam cat. Ab133357)]. CD3 and CK8/18 (clone 5D3 mouse mAb, Abcam cat. Ab17139) antibodies were included in both panels. FFPE tissue sections were stained on the Ventana Discovery Ultra autostainer, and analyzed using Tissuegnostics Strataquest software (v. 6.0.1.211). A representative image is shown in Fig. 1. RP regions went through additional manual quality control with the guidance of a pathologist to exclude normal glands that were intermixed with tumor glands. Image analysis included optimization of IF thresholding and nuclear segmentation. A CK 8/18 defined mask in tumor regions was expanded by 20 micron to generate a ring of ~1–2 full cell lengths around tumor glands and to enumerate T cell and macrophage pixel numbers, as described previously [2].
We included each variable (T cell or macrophage densities or percentages of positive tumor region in pixels) as the dependent variable of a generalized linear mixed model (GLMM) for repeated measures in which RP vs Biopsy (RP y/n) was the independent covariate under a compound symmetry covariance structure matrix. All tests were two sided with p < 0.05 considered statistically significant. We used R (R version 3.6.1 (2019-07-05) and LME4 package and SAS (9.4, SAS Institute Inc., Cary, NC, USA) to analyze the data.
CD8 T cell (CD3 + CD8+) densities within tumor regions after SBRT were decreased 2.22-fold (p = 0.001) relative to densities before SBRT, while CD4 T cell (CD3 + CD4+) densities, and Treg cell (CD4 + FOXp3) densities remained largely unchanged. The most striking change was the increase in CD11b + myeloid cells, particularly the CD68 + macrophages, and CD163+ macrophage subsets that reached 1.85-fold, 3.43-fold, and 5.61-fold change in densities after SBRT, respectively (Fig. 1).
Altogether, the immune environment within prostate tumors is significantly altered 2 weeks after SBRT. This is the first report to quantify infiltrating immune cells in situ within prostate tumors to determine local effects of SBRT in patients. This is in line with our previous flow cytometric investigation showing an equivalent shift in infiltrating immune cells post SBRT towards myeloid lineage predominance although tumor and non-tumor regions could not be distinguished at that time [3]. By spatially resolving tumor and non-tumor glands in situ, we demonstrate significant increases in macrophage densities and moderate reductions in CD8 T cell densities 2 weeks post SBRT. In a syngeneic murine model, we previously reported increases in myeloid cells 2 days after high dose per fraction radiation, followed by a transient increase of functionally active CD8 lymphocytes [4]. The changes we report here in macrophage and CD8 T cell densities 2 weeks post SBRT in patients may also be time dependent, but our analysis was limited to a single time point given the design of the clinical trial. Similar digital spatial profiling of prostate tissue before and after 2 weeks of 10 Gy delivered by HDR brachytherapy also indicated such an increase in macrophage subpopulations in the post-radiation phase [5]. The fact that this was accompanied by a strong tumor inflammatory signature points at an integrated, myeloid-centric tissue response that radiation damage is known to initiate. To reveal underlying cytokines and mechanisms that are responsible for observed changes in the immune cell infiltration, transcriptomic analyses on prostate cancer tissue post SBRT are warranted. Ultimately, the questions will be whether or not these myeloid subsets are hindering the anti-tumor immune response and if so, how they can be targeted.
References
Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, et al. Phase 1 trial of stereotactic body radiation therapy neoadjuvant to radical prostatectomy for patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2020;108:930–5. https://doi.org/10.1016/j.ijrobp.2020.06.010
Saylor J, Ma Z, Goodridge HS, Huang F, Cress AE, Pandol SJ, et al. Spatial mapping of myeloid cells and macrophages by multiplexed tissue staining. Front Immunol. 2018;9:2925. https://doi.org/10.3389/fimmu.2018.02925
Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, et al. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2021;24:135–9. https://doi.org/10.1038/s41391-020-0249-8
Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, et al. High-dose per fraction radiotherapy induces both antitumor immunity and immunosuppressive responses in prostate tumors. Clin Cancer Res. 2021;27:1505–15. https://doi.org/10.1158/1078-0432.CCR-20-2293
Keam SP, Halse H, Nguyen T, Wang M, Van Kooten Losio N, Mitchell C, et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J Immunother Cancer. 2020;8. https://doi.org/10.1136/jitc-2020-000792.
Author information
Authors and Affiliations
Contributions
NK, SDP, AUK, DS, RER, BSK, NGN designed the experiments. NK, SDP conducted the experiments. NK, SDP, TR, MBR, MLS, AUK, DS, RER, BSK, NGN analyzed data. All authors contributed to writing or critical review of the paper. NN, RER, BSK provided funding, administration, and/or resources.
Corresponding author
Ethics declarations
Competing interests
NN reports research support from Lantheus, Bayer, Janssen, and consulting fees from Oncolinea, outside of the scope of work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kane, N., Romero, T., Diaz-Perez, S. et al. Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer Prostatic Dis 26, 207–209 (2023). https://doi.org/10.1038/s41391-022-00498-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-022-00498-6
- Springer Nature Limited